Equifax vs Maximus
EFX and MMS side by side. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How EFX and MMS compare
Equifax is the larger company, worth 6.4 times as much as Maximus ($22.0B against $3.4B).
On earnings, Maximus is cheaper: it trades at 9.7× trailing earnings, against 30.4× for Equifax.
Equifax grew revenue faster over the last twelve months (10.9% versus −3.3% for Maximus).
Equifax keeps more of each dollar of sales as profit, with a net margin of 11.3% compared with 7.1% at Maximus.
Both pay dividends: Equifax yields 1.2% and Maximus 2.0%.
Maximus scores higher on the StockData Score (22 against 18 for Equifax), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | EFX | MMS |
|---|---|---|
| Size and price | ||
| Market cap | $22.0B | $3.4B |
| Share price | $188.41 | $65.38 |
| Change, 1 year | −9.8% | −21.3% |
| Change, 5 years | −34.8% | −19.6% |
| Beta (5Y) | 1.24 | 0.57 |
| Employees | 15K | 37K |
| StockData Score | ||
| Total score | 18 | 22 (better) |
| Valuation score | 3 | 6 (better) |
| Growth score | 2 | 4 (better) |
| Performance score | 4 | 6 (better) |
| Health score | 5 (better) | 4 |
| Dividend score | 4 (better) | 2 |
| Valuation | ||
| P/E | 30.4× | 9.7× (better) |
| P/S | 3.3× | 0.7× (better) |
| P/B | 4.9× | 2.0× (better) |
| EV/EBITDA | 13.6× | 7.9× (better) |
| P/FCF | 20.0× | 7.9× (better) |
| PEG | – | 0.52 |
| FCF yield | 5.0% | 12.7% (better) |
| Fair value | $232.50 | $133.48 |
| Margin of safety | 19.0% | 51.0% (better) |
| Growth | ||
| Revenue growth (TTM) | 10.9% (better) | −3.3% |
| Revenue growth, 5Y average | 8.0% | 9.4% (better) |
| Net income growth (TTM) | 12.8% | 17.3% (better) |
| EPS growth (TTM) | 17.5% | 24.7% (better) |
| EPS growth, 5Y average | 4.6% | 10.2% (better) |
| Profitability | ||
| Gross margin | 55.2% (better) | 25.6% |
| Operating margin | 18.8% (better) | 11.0% |
| Net margin | 11.3% (better) | 7.1% |
| FCF margin | 16.7% (better) | 8.3% |
| Return on equity | 15.8% | 21.1% (better) |
| Return on invested capital | 9.5% | 13.2% (better) |
| Financial health | ||
| Debt / equity | 1.16 | 0.94 (better) |
| Net debt / EBITDA | 2.51 | 2.51 (better) |
| Interest coverage | 5.4× | 6.5× (better) |
| Current ratio | 1.09 | 2.42 (better) |
| Altman Z-score | 3.51 (better) | 3.04 |
| Piotroski F-score | 8 (better) | 7 |
| Dividends and buybacks | ||
| Dividend yield | 1.2% | 2.0% (better) |
| Payout ratio | 35.0% | – |
| Years of dividend growth | 1 (better) | 0 |
| Dividend growth, 5Y average | 3.9% (better) | 1.4% |
| Buyback yield | 5.2% | 10.1% (better) |
| Shareholder yield | 6.4% | 12.1% (better) |
| Ownership | ||
| Held by institutions | 102% | 107% |
| Held by insiders | 0.69% | 2.2% |
| Insider net buying, 12 months | −$32.5M | −$254K (better) |
| Superinvestors holding | 5 | – |
| Short interest, % of float | 4.9% | 6.0% |
Go deeper
- EFX stock overview
- EFX income statement
- EFX valuation and score
- MMS stock overview
- MMS income statement
- MMS valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.